NeuroMab™ Anti-PSK9 Antibody(NRP-0422-P1558)

Product Overview

Description

NRP-0422-P1558 completely inhibited LDLR binding to PCSK9. NR1475P differentially recognized intact and cleaved PCSK9 and, thus, could be utilized for affinity purification of the cleaved form.

Immunogen

NRP-0422-P1558 epitope encompasses the PCSK9 '218-loop', which harbors the hepsin- and furin cleavage sites.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Applications

ELISA; Neut; Inhib; In Vitro; In Vivo

Relevant Diseases

Alzheimer's Disease; Stroke; Neuroinflammation

Product Properties

Formulation

PBS only

Preservatives

BSA Free

Concentration

1mg/mL

Purification

Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line

Purity

> 95% (SDS-PAGE)

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only

Target

PSK9

Official Name

PCSK9

Full Name

Proprotein Convertase Subtilisin/Kexin Type 9

Alternative Names

Proprotein Convertase Subtilisin/Kexin Type 9; Subtilisin/Kexin-Like Protease PC9; NARC-1; NARC1; PC9; Convertase Subtilisin/Kexin Type 9 Preproprotein; Hypercholesterolemia; Autosomal Dominant 3; Neural Apoptosis Regulated Convertase 1; Neural Apoptosis-Regulated Convertase 1;

Gene ID

100102(Human)

Uniprot ID

Q80W65(Human)

Product Pictures

FuncS

Figure 1 Inhibition of protease-mediated PCSK9 cleavage by mutagenesis of "loop 218" residues and antibody 3D5.

PCSK9 (1.9 μΜ) was preincubated with antibodies 3D5 or 7G7 for 20 min before treatment with 40 nM hepsin or with 80 nM furin for 6 h. Results indicate that antibody 3D5 completely inhibited PCSK9 cleavage by either protease, whereas antibody 7G7 did not.

FuncS

Figure 2 Inhibition of PCSK9 function by Ab-3D5.

Inhibition of PCSK9 binding to LDLR by biolayer interferometry. LDLR ectodomain was immobilized on the sensor of an Octet Red384 system (ForteBio; Menlo Park, CA) and binding to PCSK9 alone (Ctrl) or preincubated with Ab-3D5 or the non-blocking Ab-7G7 was measured. Results are the average of n=3 ± SD.

FuncS

Figure 3 Inhibition of PCSK9 function by Ab-3D5.

Ab-3D5 prevents LDLR degradation in HepG2 cells. HepG2 cells were treated for 4 h with buffer alone (Ctrl), with PCSK9 alone (-Ab) or with PCSK9 preincubated with increasing concentrations of the non-blocking Ab-7G7 or with Ab-3D5. Surface LDLR levels were quantified by FACS analysis and expressed as percent of control levels.

FuncS

Figure 4 shows the effect of antibody 3D5 on the activity of intact and hepsin-cleaved PCSK9 in the HepG2 assay.

FuncS

Figure 5 shows that antibody 3D5 neutralizes PCSK9 activity in a mouse model. Mice received 20 mg/kg antibody two hours before injection of 30 μg PCSK9 1 hour.

Publications